multiple myeloma Archives -

ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma

Phil Taylor ASCO 2022, BCMA, bispecific, elranatamab, Johnson & Johnson, multiple myeloma, Pfizer, teclistamab 0 Comment

Johnson & Johnson and Pfizer both highlighted new data with BCMA-targeting bispecific antibodies in patients with relapsed or

ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma

https://pharmaphorum.com/news/asco22-jj-pfizer-trade-bcma-bispecific-data-in-myeloma/

News/ News/ Oncology

J&J, Legend get EU nod for myeloma CAR-T Carvykti

Phil Taylor CAR-T therapies, Carvykti, EU, immuno-oncology, Johnson & Johnson, multiple myeloma, Oncology, regulatory approval 0 Comment

Johnson & Johnson and Legend Biotech will arrive at next week’s ASCO congress with a new EU approval

J&J, Legend get EU nod for myeloma CAR-T Carvykti

https://pharmaphorum.com/news/jj-legend-get-eu-nod-for-myeloma-car-t-carvykti/

Events/ Events/ Oncology

BCMA Targeted Therapies Summit

Rhianna Price adc, BCMA, CAR T, multiple myeloma, Oncology 0 Comment

Revolutionize your BCMA pipeline

BCMA Targeted Therapies Summit

https://pharmaphorum.com/events/bcma-targeted-therapies-summit-2/

Market Access/ News/ News

CHMP backs J&J’s myeloma CAR-T therapy Carvykti

Phil Taylor Abecma, BCMA Targeted Therapies, Bristol-Myers Squibb, CAR-T therapies, Carvykti, immuno-oncology, Johnson & Johnson, multiple myeloma, Oncology 0 Comment

Johnson & Johnson is in course for approval of its multiple myeloma CAR-T therapy Carvykti in the EU

CHMP backs J&J’s myeloma CAR-T therapy Carvykti

https://pharmaphorum.com/news/chmp-backs-jjs-myeloma-car-t-therapy-carvykti/

News/ News/ Oncology

Blackstone funds new trials of Sanofi’s Sarclisa in myeloma

Phil Taylor Blackstone, Darzalex, Johnson & Johnson, multiple myeloma, Oncology, Sanofi, Sarclisa 0 Comment

Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new

Blackstone funds new trials of Sanofi’s Sarclisa in myeloma

https://pharmaphorum.com/news/blackstone-funds-new-trials-of-sanofis-sarclisa-in-myeloma/

Market Access/ News/ News

Janssen, Legend CAR-T therapy CARVYKTI gets FDA nod

Eloise McLennan CAR-T therapies, Janssen, Legend Biotech, multiple myeloma, pharma 0 Comment

The US Food and Drug Administration (FDA) has approved a new cell-based therapy for blood cancer, developed by

Janssen, Legend CAR-T therapy CARVYKTI gets FDA nod

https://pharmaphorum.com/news/janssen-legend-cart-carvykti-fda/

News/ News/ Oncology

BMS cuts $3.15bn deal with Century for cancer cell therapies

Phil Taylor acute myeloid leukaemia, Bristol-Myers Squibb, cell therapy, Century Therapeutics, Haematology, immuno-oncology, multiple myeloma, Oncology 0 Comment

Bristol-Myers Squibb chief executive Giovanni Caforio has promised to invest in the company’s pipeline at the virtual JP

BMS cuts $3.15bn deal with Century for cancer cell therapies

https://pharmaphorum.com/news/bms-cuts-3-15bn-deal-with-century-for-cancer-cell-therapies/

Janssen J&J Johnson and Johnson pharmaceutical companies

News/ News/ Oncology

J&J goes after another FDA approval for a cancer bispecific

Phil Taylor BCMA Targeted Therapies, immuno-oncology, Janssen, Johnson & Johnson, multiple myeloma, Oncology, teclistamab 0 Comment

Johnson & Johnson’s much-touted crop of bispecific antibodies for cancer generated its first commercial product in May, and

J&J goes after another FDA approval for a cancer bispecific

https://pharmaphorum.com/news/jj-guns-for-another-fda-approval-for-a-cancer-bispecific/

Market Access/ News/ News

NICE rejects J&J’s Darzalex regimen for multiple myeloma

Phil Taylor Darzalex, HEOR, Janssen, Johnson & Johnson, multiple myeloma, NHS, NICE 0 Comment

New guidance from NICE has rejected a combination regimen based on Johnson & Johnson’s Darzalex for a group

NICE rejects J&J’s Darzalex regimen for multiple myeloma

https://pharmaphorum.com/news/nice-rejects-jj-darzalex-regimen-for-multiple-myeloma/

Trending

multiple myeloma

Login